Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141320 | 0.91 | SMN1; SMN2 (0.36) | TSHRPSMB8PSMB5MGLLL3MBTL1 | |
| SCHEMBL12185672 | 0.91 | TSHR (0.34) | TSHRPSMB8PSMB5MGLL | |
| SCHEMBL43576 | 0.90 | PSMB8 (0.35) | TSHRPSMB8PSMB5MGLL | |
| SCHEMBL21846020 | 0.89 | SMN1; SMN2 (0.38) | TSHRPSMB8PSMB5L3MBTL1 | |
| SCHEMBL21846055 | 0.89 | SMN1; SMN2 (0.38) | TSHRPSMB8PSMB5L3MBTL1 | |
| SCHEMBL31522720 | 0.88 | PSMB8 (0.34) | PSMB8PSMB5MGLL | |
| SCHEMBL14644916 | 0.84 | PSMB8 (0.33) | TSHRPSMB8PSMB5MGLL | |
| SCHEMBL2263421 | 0.84 | MGLL (0.35) | PSMB8PSMB5MGLL | |
| Ethylene Glycol SCHEMBL999673 | 0.84 | PSMB8 (0.36) | PSMB8PSMB5MGLL | |
| SCHEMBL14769218 | 0.82 | TSHR (0.36) | TSHRPSMB8PSMB5MGLLAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4299761-B1 | SURFACE-FUNCTIONALIZED OPTICAL ELEMENT | BETASENSE GMBH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260002946-A1 | SURFACE-FUNCTIONALIZED OPTICAL ELEMENT | BETASENSE GMBH (DE) | 2026-01-01 | — | — | US | disclosed |
| US-20250052675-A1 | Attenuated Total Reflectance-Based Biosensor for Conformation and Secondary Structure Analysis | BETASENSE GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| EP-3542164-B1 | METHOD FOR THE PRESELECTION OF DRUGS FOR PROTEIN MISFOLDING DISEASES | BETASENSE GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| EP-3631446-B1 | BIOSENSOR FOR CONFORMATION AND SECONDARY STRUCTURE ANALYSIS | BETASENSE GMBH (DE) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024003214-A2 | SURFACE-FUNCTIONALIZED OPTICAL ELEMENT | BETASENSE GMBH (DE) | 2024-01-04 | — | — | WO | disclosed |
| EP-4299761-A1 | SURFACE-FUNCTIONALIZED OPTICAL ELEMENT | betaSENSE GmbH (DE) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023176809-A1 | METHOD FOR PRODUCING POLYETHYLENE GLYCOL DERIVATIVE | 日油株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-11592451-B2 | Method for the preselection of drugs for protein misfolding diseases | BETASENSE GMBH (DE) | 2023-02-28 | — | — | US | disclosed |
| WO-2022118277-A1 | CARBONIC ANHYDRASE INHIBITORS SYNTHESIZED ON INTERCONNECTING LINKER CHAINS | VILNIUS UNIVERSITY (LT) | 2022-06-09 | — | — | WO | disclosed |
| US-11237176-B2 | Infrared assay detecting secondary structure profiles of alpha-synuclein | PROTHENA BIOSCIENCES LIMITED (IE) | 2022-02-01 | — | — | US | disclosed |
| EP-3943942-A1 | BIOSENSOR FOR CONFORMATION AND SECONDARY STRUCTURE ANALYSIS | betaSENSE GmbH (DE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2019192454-A9 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | 深圳大学 | 2020-01-16 | — | — | WO | disclosed |
| WO-2019192454-A1 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | 深圳大学 | 2019-10-10 | — | — | WO | disclosed |
| US-20160120994-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | BAXALTA INC (US) | 2016-05-05 | — | — | US | disclosed |
| WO-2011130577-A1 | CONTROLLED POLYPLEX ASSEMBLY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20100172967-A1 | COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7696359-B2 | Compound modified with glycerol derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20100047814-A1 | PROTEIN INTERACTION REPORTER AGENTS AND METHODS FOR USING SAME | WASHINGTON STATE UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| EP-1938795-A2 | Hair treatment composition, hair treatment agent and method for treating hair by using the same | Sunbio, Inc. (KR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002946-A1 | SURFACE-FUNCTIONALIZED OPTICAL ELEMENT | ATR, ATRIP, IGF1R | TSHR 65/4885PSMB8 567/4885PSMB5 1829/4885 |
| US-20100172967-A1 | COMPOUND MODIFIED WITH GLYCEROL DERIVATIVE | NPC1L1, SGMS1, SCARB1 | TSHR 2351/4885PSMB8 4796/4885PSMB5 3657/4885 |
| US-20160120994-A1 | BLOOD COAGULATION PROTEIN CONJUGATES | F13B, F12, F2 | TSHR 3460/4885PSMB8 1070/4885PSMB5 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.